Questions for discussion:

• Patients with decompensated cirrhosis with or without transplant options
• Patients with HCC (potentially curable)
• Patients with HCC in a palliative setting
• Patients with decompensated cirrhosis and renal impairment
• Patients with very few concomitant medications
• Patients with non-response to prior DAA therapy
• Treatment of patients with both advanced kidney and liver disease
• Data on drug to drug interactions by different regimens
• Pangenotypic failures treatment